Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

NCT00677053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
TAK-442, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
30 Years to 80 Years
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 25, 2026, 4:24 PM EDT
Not listed Phase 2 Interventional

Phase II Proof of Concept Study in Uncomplicated UTI

NCT03129295
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
MPC-SHRC, Placebo Oral Tablet
Drug
Lead sponsor
Mission Pharmacal
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Jeffersonville, Indiana • Kalamazoo, Michigan • Lawrenceville, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 2 Interventional

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

NCT00163566
View directory record Official record
Conditions
Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Drug
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
55 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

NCT01647945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
Drug
Lead sponsor
Edda Spiekerkoetter
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 2Phase 3 Interventional

Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

NCT00927914
View directory record Official record
Conditions
Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Interventions
Ranirestat, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 25, 2026, 4:24 PM EDT
Active, not recruiting Phase 2 Interventional

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

NCT02862938
View directory record Official record
Conditions
Glaucoma
Interventions
NT-501 ECT implant, Sham
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 25, 2026, 4:24 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

NCT00997152
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
JTT-654, JTT-654 Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Video-Based Coping Skills Training for Caregivers

NCT00396825
View directory record Official record
Conditions
Caregivers
Interventions
Video-based coping skills training with telephone coaching
Behavioral
Lead sponsor
Williams LifeSkills
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Oct 25, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

Role of Sleep Reactivity in Shift Work Disorder

NCT05424406
View directory record Official record
Conditions
Shift-work Disorder
Interventions
Active phototherapy, Control phototherapy, Cognitive Behavioral Therapy (CBT), Sleep education control
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

NCT05844735
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo, Ciprofloxacin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 25, 2026, 4:24 PM EDT
Not listed Phase 1Phase 2 Interventional

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

NCT02210468
View directory record Official record
Conditions
Pain, Osteoarthritis
Interventions
APIC-CF, 4 cc, APIC-CF, 2 cc, Placebo Comparator: Saline
Device · Other
Lead sponsor
Cytonics Corporation
Industry
Eligibility
21 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Townsend, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Not applicable Interventional

Computerized Assessment for Patients With Cancer

NCT00852852
View directory record Official record
Conditions
Cancer
Interventions
Electronic Self-Report Assessment - Cancer (ESRA-C)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 25, 2026, 4:24 PM EDT
Terminated Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant low dose, Deucrictibant high dose, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 4:24 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
CSB-001 Ophthalmic Solution 0.1%
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

NCT04350138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Not applicable Interventional Results available

Online Peer Networked Collaborative Learning for Managing Depressive Symptoms

NCT02841787
View directory record Official record
Conditions
Depression
Interventions
iCBT for late life depression
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
65 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 2 Interventional

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

NCT00004985
View directory record Official record
Conditions
HIV Infections
Interventions
Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
33
States / cities
Phoenix, Arizona • Beverly Hills, California • Palm Springs, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

NCT00577577
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
rhIGF-I/rhIGFBP-3, placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
21 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Not applicable Interventional

A Standardized Nursing Intervention Protocol for HCT Patients

NCT00951626
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Psychosocial Effects of Cancer and Its Treatment, Therapy-related Toxicity
Interventions
exercise intervention, telephone-based intervention, dietary intervention, educational intervention, questionnaire administration, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, assessment of therapy complications, peripheral blood stem cell transplantation, psychosocial assessment and care, quality-of-life assessment, standard follow-up care
Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 25, 2026, 4:24 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06769048
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Placebo-matching BI 1584862, BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 4:24 PM EDT
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 25, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

NCT05934487
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Interventions
Cordella™ Pulmonary Artery Sensor System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 25, 2026, 4:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Adult - Chiron Study of Bird Flu Vaccine

NCT00280033
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 25, 2026, 4:24 PM EDT